The Novel Therapeutics Committee of the North Central Cancer Treatment Group is a new committee designed to facilitate and coordinate the introduction of novel therapeutic approaches and predictors of response and toxicity into disease site programs of the NCCTG. The charge of the committee is to promote the development of novel therapeutic studies into the research programs of the NCCTG through interaction with the Mayo Clinic Cancer Center programs and programs at other organizations. The specific goals of the committee are: 1. To advice and facilitate development of selected phase Ib/II clinical trials. These trials could include combinations of novel agents with standard drugs or combinations of approved drugs. 2. To develop selected pharmacokinetic drug studies, such as population- based pharmacokinetics, testing of limited sampling models, drug disposition in organ dysfunction, and drug pharmacokinetics/pharmacodynamics in the elderly in collaboration with the disease site committees of the NCCTG. 3. To evaluate novel markers of response and toxicity that have been identified in research programs of the Mayo Clinic Cancer Center and other organizations. Such markers would be selected in discussions with the Laboratory Science Committee and specific disease site chairs. The significance of the work proposed is that the studies will build a logical progression from the laboratory through phase I into phase II evaluation. The phase II evaluation is critical to the confirmation of the mechanisms which have been delineated in the preclinical models using biomarkers that have been identified as potentially feasible to apply in broader clinical testing during phase I testing. Previous work that has already been undertaken and proposed projects are detailed in the report that follows.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA025224-23S1
Application #
6665609
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-01-01
Project End
2002-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
23
Fiscal Year
2002
Total Cost
$78,870
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Schiff, David; Jaeckle, Kurt A; Anderson, S Keith et al. (2018) Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer 124:1455-1463
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Zhang, Qiang; Freidlin, Boris; Korn, Edward L et al. (2017) Comparison of futility monitoring guidelines using completed phase III oncology trials. Clin Trials 14:48-58
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Larsen, Jeremy T; Shanafelt, Tait D; Leis, Jose F et al. (2017) Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. Am J Hematol 92:759-763
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828

Showing the most recent 10 out of 718 publications